Aandelen in “Farmaceutische producten: Andere”

Aandeel Datum Koers Evolutie
vlag Pacira BioSciences Inc 3/03 22,100 USD
+3,85% 		+3,85%
vlag Perrigo Company plc 3/03 11,390 USD
-7,70% 		-7,70%
vlag Perspective Therapeutics Inc 3/03 5,170 USD
-3,36% 		-3,36%
vlag Prestige Consumer Healthcare Inc 3/03 69,000 USD
+0,69% 		+0,69%

Nieuws over “Farmaceutische producten: Andere”

3/03 · MySize Issues CEO Letter to Stockholders · Persbericht

3/03 · MySize Issues CEO Letter to Stockholders · Persbericht

3/03 · BellRing Brands (BRBR) Facing Securities Class Action Amid Questions About Destocking, Consumption and Competition - Hagens Berman · Persbericht

3/03 · BellRing Brands (BRBR) Facing Securities Class Action Amid Questions About Destocking, Consumption and Competition - Hagens Berman · Persbericht

3/03 · BellRing Brands (BRBR) Facing Securities Class Action Amid Questions About Destocking, Consumption and Competition - Hagens Berman · Persbericht

3/03 · BellRing Brands (BRBR) Facing Securities Class Action Amid Questions About Destocking, Consumption and Competition - Hagens Berman · Persbericht

3/03 · Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

3/03 · Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions · Persbericht

28/02 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

28/02 · BellRing Brands, Inc. Securities Fraud Class Action Result of Inventory Issues and 52% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

26/02 · Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders · Persbericht

26/02 · BellRing Brands, Inc. (BRBR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

26/02 · Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

26/02 · Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations · Persbericht

26/02 · Argenx boekt meer dan 1 miljard dollar jaarwinst · Tijd.be (€)

Het Gentse biotechbedrijf Argenx blijft in volle vaart vooruitgaan. De jaarresultaten maken nog eens duidelijk dat het bedrijf met zijn medicijn Vyvgart puur goud in handen heeft.

26/02 · Blockbuster van Argenx scoort met studieresultaten in extra aandoening · Tijd.be (€)

Vyvgart, de multi-inzetbare behandeling van het Gentse biotechbedrijf Argenx, boekte goede resultaten als potentiële behandeling van de ziekte oculaire myasthenia gravis.

25/02 · LEVI & KORSINSKY, LLP: COMPETITIVE THREAT DISCLOSURES CHALLENGED IN BELLRING BRANDS SECURITIES ACTION · Persbericht

25/02 · Beleggersagenda van donderdag 26 februari: Bel20-farmatenoren rapporteren · Tijd.be (€)

De farmagroepen Argenx en UCB, samen goed voor ruim een kwart van de Brusselse sterrenkorf Bel20, rapporteren de cijfers over 2025 en de outlook voor 2026.

25/02 · Decibel Announces Sale of Creston Property and Consolidation of Cultivation Facilities · Persbericht

25/02 · CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® · Persbericht

25/02 · Joint U.S. Commercialization of RedHill's Talicia® Commences · Persbericht

Mijn selecties